Press Releases

Biotech stock to watch! Cardiol Therapeutics announces positive Phase 1 Trial results

16 Apr 2021 | by: Kirsteen Mackay

Biotech stock Cardiol Therapeutics Inc. (TSX:CRDL | OTCQX:CRTPF | FSE: CT9) is setting the stage for an exciting 2021, as its mission to treat cardiovascular disease picks up pace. In a press release dated April 12, Cardiol Therapeutics announced the topline results of its latest Phase I clinical trial. And these are very positive indeed.

Developing cannabidiol based CardiolRx

The clinical trial involved testing its proprietary treatment, CardiolRx™, on a randomized selection of 52 subjects aged between 25 and 60 years old.

CardiolRx™ is a pharmaceutically produced oral cannabidiol formulation that is THC-free (<10 ppm). It is being developed by Cardiol Therapeutics specifically to treat acute and chronic inflammation associated with heart disease.

But CardiolRx™ is not the only cannabidiol medication developed by Cardiol Therapeutics. The Company recently commercialized Cortalex to the Canadian medicinal cannabidiol market.

How did the Phase I study work?

The Phase I single and multiple ascending dose trial took place over six days. Furthermore, it’s among the most comprehensive Phase I clinical trials ever conducted using a pharmaceutically produced cannabidiol formulation on adults.

To meet stringent requirements, patients were split into two groups containing a mix of active and placebo participants. It was a double-bind study testing the drug’s safety, tolerability, and pharmacokinetic profile of CardiolRx™ at various doses.

They took regular blood samples from the subjects to measure levels of cannabidiol and its two main metabolites.

These topline results show CardiolRx™ to be safe and generally well tolerated at all dose levels. And with no serious adverse events reported in the study, it’s a very reassuring step in ensuring ongoing progress to commercializing the drug.

Get our FREE IN-DEPTH REPORT to discover the wealth generating potential of investing in Cardiol Therapeutics!

Why the success of this Phase I trial matters

From here, Cardiol Therapeutics wants to progress to a Phase II international trial in acute myocarditis, an inflammatory condition of the heart. This remains a leading cause of sudden cardiac death in children and young people under 35 years old.

To get to this stage, it must win the FDA’s stamp of approval, and the results of this Phase I study should help. Thus, it intends to file an IND application with the FDA to this end.

US Covid-19 cardiovascular study

In addition to the Phase I study conducted to test dosing, the Company is set to get underway with a Phase II/III clinical trial in the US. This is investigating the cardioprotective properties of CardiolRx™ in 422 hospitalized patients suffering from Covid-19 that also have a history of, or risk factors for, cardiovascular disease.

The reason this separate trial can start is due to the urgent nature of dealing with Covid-19 and its detrimental effect on patients’ wellbeing.

To meet FDA approval, any new drug must undergo stringent testing through certified clinical trials. Consequently, the results of the Phase I study show its findings to be consistent with published results for oral cannabidiol formulations. Thus, it will serve as a guideline for the dosing regimen adopted by the ongoing US Phase II/III trial in Covid-19 patients.

On a mission to beat cardiovascular disease

Cardiol Therapeutics is developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. These are life-threatening conditions that kill millions every year. Therefore, breakthrough treatments are increasingly sought after and in high demand.

Accordingly, Cardiol is also developing a subcutaneous formulation of CardiolRx™ and other anti-inflammatory therapies to treat chronic heart failure. It’s a leading cause of death and hospitalization in North America. In fact, the associated annual healthcare costs are believed to exceed $30 billion in the US alone.

GET OUR SPECIAL REPORT ON CARDIOL’S REVOLUTIONARY TREATMENT AND HOW EARLY INVESTORS COULD PROFIT.

IMPORTANT NOTICE AND DISCLAIMER

Paid Advertisement

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of forty thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

Changes in Share Trading and Price

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

No Offer to Sell or Buy Securities

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

Information

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

No Financial Advice

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

Forward Looking Statements

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

Indemnification/Release of Liability

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

Terms of Use and Disclaimer

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.

Intellectual Property

All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.

Authors: ValueTheMarkets

Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

  • Kirsteen Mackay does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.
  • Kirsteen Mackay has been paid to produce this piece by the company or companies mentioned above.
  • Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.
  • Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production this piece by the company or companies mentioned above.

More News & Analysis

Crypto crash: So many broken promises

Crypto is once again crashing and the bulls and bears are at loggerheads. Meanwhile Coinbase is being sued and criticized for outages during volatility.